Thrivent Financial for Lutherans Increases Holdings in Lam Research Corporation $LRCX

Thrivent Financial for Lutherans increased its holdings in shares of Lam Research Corporation (NASDAQ:LRCX) by 29.6% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 125,693 shares of the semiconductor company’s stock after acquiring an additional 28,716 shares during the period. Thrivent Financial for Lutherans’ holdings in Lam Research were worth $12,237,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Sava Infond d.o.o. boosted its stake in Lam Research by 3.1% during the second quarter. Sava Infond d.o.o. now owns 75,250 shares of the semiconductor company’s stock valued at $7,325,000 after buying an additional 2,250 shares during the last quarter. Horizon Bancorp Inc. IN purchased a new stake in shares of Lam Research during the 2nd quarter worth approximately $389,000. Empowered Funds LLC boosted its position in shares of Lam Research by 10.5% during the 1st quarter. Empowered Funds LLC now owns 187,472 shares of the semiconductor company’s stock valued at $13,629,000 after acquiring an additional 17,833 shares during the last quarter. Genus Capital Management Inc. bought a new stake in Lam Research in the second quarter worth $14,476,000. Finally, Glass Wealth Management Co LLC raised its stake in Lam Research by 8.5% during the second quarter. Glass Wealth Management Co LLC now owns 28,870 shares of the semiconductor company’s stock valued at $2,810,000 after purchasing an additional 2,270 shares in the last quarter. 84.61% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lam Research

In related news, Director Bethany Mayer sold 1,298 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $159.99, for a total value of $207,667.02. Following the completion of the transaction, the director owned 1,652 shares of the company’s stock, valued at $264,303.48. The trade was a 44.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ava Harter sold 9,010 shares of the company’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $157.47, for a total value of $1,418,804.70. Following the sale, the insider owned 56,786 shares of the company’s stock, valued at approximately $8,942,091.42. This represents a 13.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 102,608 shares of company stock valued at $14,916,496. 0.31% of the stock is owned by corporate insiders.

Lam Research Trading Down 5.1%

Shares of NASDAQ LRCX opened at $154.98 on Thursday. Lam Research Corporation has a twelve month low of $56.32 and a twelve month high of $169.69. The firm has a market cap of $194.66 billion, a PE ratio of 34.14, a price-to-earnings-growth ratio of 1.68 and a beta of 1.77. The business has a fifty day simple moving average of $153.54 and a two-hundred day simple moving average of $121.88. The company has a quick ratio of 1.60, a current ratio of 2.21 and a debt-to-equity ratio of 0.37.

Lam Research (NASDAQ:LRCX) last posted its quarterly earnings results on Wednesday, October 22nd. The semiconductor company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.04. The business had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.23 billion. Lam Research had a return on equity of 60.60% and a net margin of 29.66%.The business’s revenue was up 27.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.86 EPS. Lam Research has set its Q2 2026 guidance at 1.050-1.250 EPS. Analysts expect that Lam Research Corporation will post 3.71 earnings per share for the current fiscal year.

Lam Research Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 7th. Stockholders of record on Wednesday, December 3rd will be paid a dividend of $0.26 per share. The ex-dividend date is Wednesday, December 3rd. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.7%. Lam Research’s dividend payout ratio (DPR) is currently 22.91%.

Analyst Ratings Changes

LRCX has been the subject of a number of analyst reports. Cowen reaffirmed a “buy” rating on shares of Lam Research in a report on Thursday, October 23rd. BNP Paribas Exane lifted their price objective on shares of Lam Research from $80.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Lam Research from $150.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Wells Fargo & Company boosted their target price on Lam Research from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Thursday, October 23rd. Finally, Oppenheimer set a $200.00 price objective on Lam Research and gave the company an “outperform” rating in a report on Thursday, October 23rd. Twenty-six analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Lam Research currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.54.

Lam Research Company Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.